Stratatech Corporation is a regenerative medicine company focused on the commercialization of unique, proprietary skin substitute products for therapeutic and research uses. The company was founded in 2000 on a commitment to dramatically improve the treatment options and outcomes for patients with burns and other severe skin injuries. Stratatech’s world-class team strives to uphold this commitment every day. The company’s StrataGraft® tissue is a next-generation tissue-engineered living skin substitute that exhibits the biological structure and function of natural human skin. In 2008, Stratatech successfully completed a Phase I/II clinical trial of StrataGraft® tissue for temporary skin replacement prior to autografting. The company markets a 24-well-plate version of its skin substitute tissue as StrataTest®. This research-use-only product can be used by pharmaceutical, biotechnology and consumer goods companies as an alternative to animal testing to evaluate the effects of new chemicals and compounds on human skin. Stratatech’s valuable product pipeline, based on its patented human NIKS® cells, is comprised of additional, next-generation skin substitute products that possess numerous advantages over products generated by conventional means. Stratatech’s pipeline includes a suite of ExpressGraft™ skin substitute products that have been genetically engineered to overproduce natural, human wound-healing factors that reduce infection, improve blood flow and increase the rate of healing.